修订版HOME-CoV评分:急诊科疑似或确诊COVID-19患者风险分层模型的推导与验证
本研究基于2020年4–5月法国、摩纳哥和比利时34个急诊科的前瞻性多中心研究数据,推导并验证修订版HOME-CoV评分,用于判断疑似或确诊COVID-19患者能否居家治疗。推导队列1696例中65例(3.8%)在7天内需无创或有创通气或死亡,验证队列1304例中22例(1.7%)病情进展。修订版评分含7项临床标准,推导队列AUC 87.6(95%CI 84.7–90.6),验证队列AUC 85.8(95%CI 80.6–91.0),低风险和高风险界值分别为<2分和>3分。验证队列中<2分将73%患者归为低风险,灵敏度0.77(0.55–0.92),阴性预测值0.99(0.99–1.00)。作者认为该评分可能实现准确风险分层,并安全地将相当比例患者归为居家治疗。
要点
- 修订版HOME-CoV评分含7项临床标准,无需实验室检查,低风险界值为<2分,高风险界值为>3分。
- 验证队列中<2分将73%患者归为低风险,灵敏度0.77(0.55–0.92),阴性预测值0.99(0.99–1.00)。
- 推导队列AUC 87.6(95%CI 84.7–90.6),验证队列AUC 85.8(95%CI 80.6–91.0)。
- 推导队列1696例中65例(3.8%)7天内需无创或有创通气或死亡;验证队列1304例中22例(1.7%)病情进展。
- 作者认为修订版评分可能准确风险分层,并安全地将相当比例疑似或确诊COVID-19患者归为居家治疗。
适用人群与场景
- 在法国、摩纳哥和比利时34个急诊科就诊的疑似或确诊COVID-19患者,纳入时间为2020年4月至5月。
- 推导样本对应原研究的观察期,验证样本对应原研究的干预期。
诊断标准与关键阈值
- 修订版HOME-CoV评分含7项临床标准,无需实验室检查。
- 低风险界值为<2分,高风险界值为>3分;两个界值分别以灵敏度>0.9和特异度>0.9定义。
研究设计与关键结果
- 研究类型为基于前瞻性多中心研究的推导与回顾性验证,数据来自法国、摩纳哥和比利时34个急诊科2020年4月至5月的疑似或确诊COVID-19患者;主要结局为纳入后7天内需无创或有创通气或全因死亡。
- 推导队列1696例,其中65例(3.8%)在7天内需无创或有创通气或死亡;验证队列1304例,其中22例(1.7%)病情进展。
- 修订版HOME-CoV评分含7项临床标准,推导队列AUC 87.6(95%CI 84.7–90.6),验证队列AUC 85.8(95%CI 80.6–91.0)。
- 验证队列中评分<2分将73%患者归为低风险,灵敏度0.77(0.55–0.92),阴性预测值0.99(0.99–1.00)。
- 修订版评分在验证队列中与原始HOME-CoV、qCSI、qSOFA、CRB65和SMART-COP进行了比较。
证据类型、等级与局限
- 证据类型:基于前瞻性多中心研究的评分推导与回顾性验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原作者认为,修订版HOME-CoV评分无需实验室检查,可能实现准确风险分层,并安全地将相当比例疑似或确诊COVID-19患者归为居家治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The HOME-CoV (Hospitalisation or Outpatient ManagEment of patients with SARS-CoV-2 infection) score is a validated list of uniquely clinical criteria indicating which patients with probable or proven COVID-19 can be treated at home. The aim of this study was to optimise the score to improve its ability to discriminate between patients who do and do not need admission.
METHODS: A revised HOME-CoV score was derived using data from a previous prospective multicentre study which evaluated the original Home-CoV score. Patients with proven or probable COVID-19 attending 34 EDs in France, Monaco and Belgium between April and May 2020 were included. The population was split into a derivation and validation sample corresponding to the observational and interventional phases of the original study. The main outcome was non-invasive or invasive ventilation or all-cause death within 7 days following inclusion. Two threshold values were defined using a sensitivity of >0.9 and a specificity of >0.9 to identify low-risk and high-risk patients, respectively. The revised HOME-CoV score was then validated by retrospectively applying it to patients in the same EDs with proven or probable COVID-19 during the interventional phase. The revised HOME-CoV score was also tested against original HOME-CoV, qCSI, qSOFA, CRB65 and SMART-COP in this validation cohort.
RESULTS: There were 1696 patients in the derivation cohort, of whom 65 (3.8%) required non-invasive ventilation or mechanical ventilation or died within 7 days and 1304 patients in the validation cohort, of whom 22 (1.7%) had a progression of illness. The revised score included seven clinical criteria. The area under the curve (AUC) was 87.6 (95% CI 84.7 to 90.6). The cut-offs to define low-risk and high-risk patients were <2 and >3, respectively. In the validation cohort, the AUC was 85.8 (95% CI 80.6 to 91.0). A score of <2 qualified 73% of patients as low risk with a sensitivity of 0.77 (0.55-0.92) and a negative predictive value of 0.99 (0.99-1.00).
CONCLUSION: The revised HOME-CoV score, which does not require laboratory testing, may allow accurate risk stratification and safely qualify a significant proportion of patients with probable or proven COVID-19 for home treatment.
参考来源
- Douillet D, Riou J, Morin F, et al. Derivation and validation of a risk-stratification model for patients with probable or proven COVID-19 in EDs: the revised HOME-CoV score. Emerg Med J. 2024. PMID: 38365436. doi:10.1136/emermed-2022-212631
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。